OUR TEAM

Dr. Vadim Igal, CEO
Ophthalmology Resident, Lady Davis hospital

Dr. Adi Berco, COO
MD Technion
Law and Economics, Tel Aviv University

Shelly Boneh, CPO
M.Sc Technion, Industrial Design, Bezalel Academy

Lior Berko, CTO
B.Sc Technion, Computer science

Stage: Pre-Seed
Industry: Health technology
Market size: $12.1 billion
Investment opportunity: $150,000
Use of funds: development and testing of the initial prototype through clinical trials

WHY CHOOSE US

Here is the reason

WHAT SETS US APART FROM THE COMPETITION IS THE PIONEERING NATURE OF OUR PRODUCT, WHICH ENSURES THE PROPER ENTRY OF EYE DROPS. ITS ERGONOMIC DESIGN, UNIVERSAL COMPATIBILITY, AND POTENTIAL FOR INTEGRATION WITH ANY EYE DROP BOTTLE RENDER IT UNIQUE IN THE MARKET.

OUR MISSION

Preventing blindness in 80 million worldwide by providing a user-friendly method for lifelong eye drop use against Glaucoma, the main cause of irreversible blindness.

PROBLEM

The challenge at hand is the prevalent loss of sight among Glaucoma patients due to the challenge of chronic eye drop use. This is primarily attributed to forgetfulness and the inherent intricacies of managing multiple eye drop types.

OUR SOLUTION

Mobile app
Our customer service software makes it easy to connect with customers and help them succeed.

SOLUTION

A user-friendly mobile app, a smart "add on" device that verifies correct eye drop application, and an AI-powered system that analyzes data. By integrating these components, patients are empowered to take charge of their eye care, while allowing predictions for disease progression to more efficiently allocate healthcare resources.

REVENUE

B2B: customers can purchase the smart "add on" or access the app for free.

B2C: we offer the product to pharmaceutical companies as a complementary tool or sell subscriptions to medical insurance companies, positioning our product as a pivotal asset for managing chronic eye diseases.

www.eyehope.com eyehopeteam@gmail.com Haifa City, IL